Literature DB >> 9143072

Sleep-promoting and hypothermic effects of daytime melatonin administration in humans.

R J Hughes1, P Badia.   

Abstract

Sleep-promoting and hypothermic effects of orally administered melatonin during the daytime were assessed using a placebo-controlled, double-blind, cross-over design. Following a 7-hour nighttime sleep opportunity, healthy young male subjects (n = 8) were given either a placebo or one of three doses of melatonin (1 mg, 10 mg, and 40 mg) at 1000 hours. Sleep was polygraphically assessed in a 4-hour sleep opportunity from 1200 to 1600 hours. All doses of melatonin significantly shortened the latency to sleep onset. Melatonin also significantly increased total sleep time and decreased wake after sleep onset (WASO). Sleep following melatonin administration contained significantly more stage 2 and less stage 3-4, while stage 1 and rapid eye movement (REM) sleep were unaffected. In addition to the sleep-promoting effects, melatonin completely suppressed the normal diurnal rise of core body temperature. These data suggest that melatonin may be an effective method of promoting sleep for individuals attempting to sleep during their subjective day, such as shiftworkers and individuals rapidly traveling across multiple time zones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143072

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  29 in total

1.  Post-exercise cold water immersion: effect on core temperature and melatonin responses.

Authors:  Elisa Robey; Brian Dawson; Shona Halson; Carmel Goodman; Warren Gregson; Peter Eastwood
Journal:  Eur J Appl Physiol       Date:  2012-06-16       Impact factor: 3.078

2.  Sleep disorders and inflammatory disease activity: chicken or the egg?

Authors:  Parth J Parekh; Edward C Oldfield Iv; Vaishnavi Challapallisri; J Catsby Ware; David A Johnson
Journal:  Am J Gastroenterol       Date:  2014-08-26       Impact factor: 10.864

3.  Intrinsic period and light intensity determine the phase relationship between melatonin and sleep in humans.

Authors:  Kenneth P Wright; Claude Gronfier; Jeanne F Duffy; Charles A Czeisler
Journal:  J Biol Rhythms       Date:  2005-04       Impact factor: 3.182

4.  Effects of melatonin administration on daytime sleep after simulated night shift work.

Authors:  K M Sharkey; L F Fogg; C I Eastman
Journal:  J Sleep Res       Date:  2001-09       Impact factor: 3.981

5.  Ageing and the circadian and homeostatic regulation of human sleep during forced desynchrony of rest, melatonin and temperature rhythms.

Authors:  D J Dijk; J F Duffy; E Riel; T L Shanahan; C A Czeisler
Journal:  J Physiol       Date:  1999-04-15       Impact factor: 5.182

6.  Use of transdermal melatonin delivery to improve sleep maintenance during daytime.

Authors:  D Aeschbach; B J Lockyer; D-J Dijk; S W Lockley; E S Nuwayser; L D Nichols; C A Czeisler
Journal:  Clin Pharmacol Ther       Date:  2009-07-15       Impact factor: 6.875

7.  Sleep, Hormones, and Circadian Rhythms throughout the Menstrual Cycle in Healthy Women and Women with Premenstrual Dysphoric Disorder.

Authors:  Ari Shechter; Diane B Boivin
Journal:  Int J Endocrinol       Date:  2010-01-18       Impact factor: 3.257

8.  Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans.

Authors:  Shantha M W Rajaratnam; Benita Middleton; Barbara M Stone; Josephine Arendt; Derk-Jan Dijk
Journal:  J Physiol       Date:  2004-09-30       Impact factor: 5.182

9.  A meta-analytic approach to quantify the dose-response relationship between melatonin and core temperature.

Authors:  K Marrin; B Drust; W Gregson; G Atkinson
Journal:  Eur J Appl Physiol       Date:  2013-06-16       Impact factor: 3.078

Review 10.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.